Get access to our best features

Pfizer says RSV vaccine is effective at preventing severe illness in babies

Summary by Ground News
Preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close. New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.
Published 3 months ago · New York, United States

News Articles

More Filters
All
Left
Center
Right

Strong RSV vaccine data lifts hopes after years of futility

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.

3 months ago·Toronto, Canada
Read Full Article

Vaccinating pregnant women with new RSV vaccine helped protect newborns: Pfizer - National

Pfizer's maternal vaccine is the same recipe it tested successfully in older adults and it plans to seek Food and Drug Administration approval for those vaccinations by year's end.

3 months ago·Toronto, Canada
Read Full Article

Strong RSV vaccine data lifts hopes

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall. (Nov. 1)

3 months ago·United States
Read Full Article

Strong RSV vaccine data lifts hopes after years of futility

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.

3 months ago·United States
Read Full Article

Strong RSV vaccine data lifts hopes after years of futility

A new study suggests vaccinating pregnant women protects their newborns from the common but scary respiratory virus called RSV

3 months ago·United States
Read Full Article

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.

3 months ago·Atlanta, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

66% of the sources are Center
CNN
HuffPost
Global News
USA Today
Associated Press News
abc News
The Washington Post
Los Angeles Times
+16
CTV News
CNBC
KRDO
The Hill
Pioneer Press
Winnipeg Free Press
+52
National Post
MY Northwest
Times Live
Wall Street Journal
The Billings Gazette
The National Desk
+2
L 26%
C 66%
 
See less detail